Eli Lilly and Company

Don Richard Finley

Cynthia Darshini Jesudason

Philip Arthur Hipskind

Freddie Craig Stevens

Takako Takakuwa

Daniel Jon Sall

Jolie Anne Bastian

William Joseph Hornback

Vincent Patrick Rocco

Theo Schotten

Patrick Gianpietro Spinazze

Richard Todd Pickard

John Arnold Werner

Robert Alan Gadski

Andrew Michael Ratz

Lisa Selsam Beavers

John Xiaoqiang He

William George Trankle

Gerd Reuhter

Henry U Bryant

Ken Matsumoto

Terry Patrick Finn

Grant Mathews Vaught

Rushad Eruch Karanjawala

Britta Evers

Terry Patrick Eli Lilly And Company Finn

The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. (Formula I). 

Histamine H3 receptor agents, preparation and therapeutic uses

The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine&#x2014;H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor&#x2014;related diseases 

The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. 

Pyrrolidine derivatives as histamine H3 receptor antagonists

The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. 

The present invention relates to a &#x3b2;adrenergic receptor agonist of formula (I), wherein R is C&#x2013;Calkyl or (C&#x2013;Ccycloalkyl)C&#x2013;Calk-di-yl: Ris H, CN, halo; C&#x2013;Calkyl, C&#x2013;Chaloalkyl, COR, CONRR, NRCOR, NRR, OR, SR, SOR, S0Ror SONRR; Ris H, halo or C&#x2013;Calkyl; Ris H or C&#x2013;Calkyl; Rand Rare independently H or C&#x2013;Calkyl Ris hydrogen, optionally substituted phenyl or optionally substituted heterocycle; X is absent or is OCHor SCH; Xis absent or C&#x2013;Calk-di-yl; and Xis absent or is O, S, NH, NHSO, SONH or CH; or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity 

[object Object]

The present invention relates to a &#x3b2;3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g., for treating Type 2 diabetes and/or obesity 

&#x3b2;3 adrenergic agonists

The present invention relates to a &#x3b2;3 adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.

3-substituted oxindole &#x3b2;3 agonists

The present invention relates to a &#x3b2;adrenergic receptor agonist of formula I:or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.

The present invention relates to a &#x3b2;3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.

3-substituted oxindole &#x3b2;-3 agonists

The present invention is directed to compounds of Formula I: ##STR1## wherein: n is 2 or 3;

Growing community of inventors

Greenwood, IN, United States of America

Don Richard Finley